# Benign Hepatic Cyst in the Setting of Markedly Elevated CA 19-9

**AUTHORS:**
Williams LE; Chan EY; Pool MD; Thomas MB

**CORRESPONDENCE AUTHOR:**
Lauren Williams, MD  
Department of Surgery  
1750 W. Harrison Street, Jelke-775  
Chicago, IL 60612  
Phone: (618) 919-1881  
E-mail: lauren_e_williams@rush.edu

**AUTHOR AFFILIATION:**
Rush Medical Center, Department of Surgery, Chicago, IL

---

## Background
A 34-year-old female presented with an enlarging hepatic mass in the setting of markedly elevated serum CA 19-9.

## Summary
The 34-year-old patient presented with intermittent right upper quadrant pain, early satiety, and abdominal bloating. CT revealed a large cystic mass in the left lobe of the liver with septation and compression of the gallbladder. Serum CA 19-9 was 45,266. She underwent resection. Despite this markedly elevated serum CA 19-9, final pathology was consistent with a benign hepatic cyst.

## Conclusion
While serum CA 19-9 is a biomarker associated with biliopancreatic malignancy, it is also associated with a number of benign etiologies and cannot reliably be used to differentiate between the two. This case report demonstrates the inability of serum CA 19-9 to predict malignant versus benign etiology of biliopancreatic masses.

## Keywords
Hepatic cyst; CA 19-9

---

**DISCLOSURE STATEMENT:**
The authors have no conflicts of interest to disclose.

---

Case Description

Serum carbohydrate associated antigen 19-9 is a well-known tumor marker of biliopancreatic malignancies. However, a number of benign pathologies are also associated with an elevated serum CA 19-9. Here, the authors discuss a patient with markedly elevated serum CA 19-9 in the setting of a simple biliary cyst.

The patient is a 34-year-old female without significant past medical history presented for further evaluation of a cystic liver mass. She complained of severe, intermittent, right upper quadrant pain associated with non-bloody, non-bilious emesis. She endorsed early satiety and abdominal bloating. She had a positive family history of cholelithiasis. She denied weight loss, fevers, chills, or night sweats. She reported several similar episodes of abdominal pain and associated symptoms, for which she was seen at various outside emergency departments on three to four separate occasions. During these encounters, she had a right upper quadrant ultrasound that revealed a 10.8 x 16.1 x 9.5 cm cystic lesion with layering, debris, and septation and a CT A/P with contrast, revealing a 5.8 x 4.8 x 3.7 cm hypodense mass within the medial segment of the left lobe with septation, compression of the gallbladder, and no evidence of intra- or extrahepatic biliary dilatation. She was referred to our institution for further workup and evaluation.

A CT A/P with contrast was significant for a large, hypodense, multiloculated, exophytic, cystic mass in the left lobe that measured 12.6 x 11.6 x 9.9 cm, a marked increase in size from that on prior imaging, was compressing the adjacent gallbladder, duodenum, and stomach (Figure 1) still without any intra- or extrahepatic biliary dilatation. At that time, all liver enzyme levels were within normal limits.

The patient’s physical exam was remarkable only for a large palpable mass in the right upper quadrant. At that time, serum alpha fetoprotein level was within normal limits, but tumor marker serum CA 19-9 was markedly elevated at 45,266 units/mL. Given the aforementioned radiologic findings, suspicion for cystadenoma was highest on the authors’ differential; however, the possibility of malignancy was also discussed with the patient, given significant elevation of CA19-9 tumor marker. Resection of the mass with concurrent open cholecystectomy was deemed the next appropriate step in management.

On April 25, 2018, the patient was taken to the operating room for an extended left lobectomy. Liver segments II, III, IV, and a portion of V were resected with the gallbladder en bloc (Figures 2 through 4). The adjacent right portal vein was carefully preserved throughout this dissection. The middle and left hepatic veins were identified, ligated, and over-sewn. The specimen was sent to pathology for frozen sections and negative margins were confirmed prior to closure. Postoperative course was uneventful, and the patient went home on postoperative day four.

Figure 1. a) Cross-sectional; and b) coronal imaging of mass, respectively.

Figure 2. Hepatic mass en vivo.

Figure 3. Extended left lobectomy with gallbladder en bloc and mass en vivo.
Pathology later confirmed that the mass was a 13 x 7.5 x 6 cm benign, simple hepatic cyst with mild portal hepatitis and steatosis. Of note, only a small portion of the cyst had an epithelial lining. The areas lacking an epithelium had a local predominance of muciphages as well as scattered neutrophils and lymphocytes. There was also a great deal of collagen and stromal tissue forming a capsule around the mass with surrounding compressed hepatic parenchyma (Figure 5 and Figure 6).

The patient was later seen in our clinic for follow-up. She was doing well at that time, with minimal pain as well as denied nausea, vomiting, fevers, and chills. Her serum CA 19-9 had down trended to 51 units/mL at this visit. She followed up again a few weeks later in our clinic and continued to do well. Serum CA 19-9 had decreased further to 29 units/mL. Two months later, a CT A/P with contrast was completed due to a recurrence of right upper quadrant pain that showed postsurgical changes without any recurrence of or residual mass and no acute intraabdominal processes. Her pain was deemed likely musculoskeletal in nature given her recent return to work. The patient has not had any recurrent or new symptoms since that time.

**Discussion**

Serum carbohydrate associated antigen 19-9 is a well-known tumor marker of biliopancreatic malignancies. However, a number of benign pathologies are also associated with an elevated serum CA 19-9.\(^1\) While these elevations are typically mild (<200 u/mL), few etiologies, including obstructive jaundice, acute liver failure, acute hepatitis, alcoholic liver disease, and acute pancreatitis, have been known to cause more marked elevations (>1000 u/mL).\(^1\)

Mucins carrying the CA 19-9 epitope are secreted by normal biliary cells.\(^5\) An elevated serum CA 19-9 indicates inflammation of the biliary tree or surrounding parenchyma with resultant biliary leakage into systemic circulation.\(^5\) The biliary epithelium that lines hepatic cyst walls has been proposed as the underlying etiology of elevated CA 19-9 in most benign cases.\(^5\) In cases of an infected cyst, these levels are even further elevated due to the local inflammatory state.\(^5\)

Although using serum tumor marker CA 19-9 has been proposed as a diagnostic tool for differentiating malignant and premalignant lesions from benign cysts, studies have not supported this notion. Numerous studies have shown that neither serum nor cystic concentrations of CA 19-9 are reliable in differentiating hepatic cystadenomas and cystadenocarcinomas from simple hepatic cysts.\(^2-4\) However, the serum CA 19-9 derangements cited in these reports were much milder than that seen in our patient, all <200 u/mL. Despite the markedly elevated serum CA 19-9 of the patient, pathology was consistent with a benign hepatic cyst, further underscoring the poor predictive value of serum CA 19-9 in differentiating benign versus malignant biliopancreatic etiologies. Cyst aspirate was not obtained during this case and, thus, we are unable to further comment on cystic concentrations of CA 19-9 in this report.

As described above, our patient’s mass was lacking a significant portion of the circumferential epithelial lining. The presence of numerous muciphages and occasional neutrophils and lymphocytes on pathology are indicative of a local inflammatory reaction leading to breakdown of the
epithelial barrier surrounding the cyst. Breakdown of this epithelial lining would have allowed excess leakage of cyst contents (mucin) into the serum, leading to an elevated serum CA 19-9, as was seen in the patient’s lab results. There was also significant collagen and stromal tissue present at the periphery of the cyst, again indicative of a local inflammatory reaction.

Additionally, elevation of serum CA 19-9 in the setting of heavy black tea consumption has been observed. Al-Janabi and Tawfeeq described serum CA 19-9 elevation in 43 percent of subjects consuming large amounts of black tea. However, the maximum value observed among participants was 105 in this study. A 2003 case report described an individual with CA 19-9 levels elevated to >1,000 without any responsible etiology identified other than heavy tea consumption and, most notably, this value down-trended to normal limits with cessation of tea consumption. The patient endorses drinking several glasses of black tea on a daily basis.

While heavy consumption of black tea may have further contributed to or amplified our patient’s CA 19-9 elevation, it is likely that the histologic evidence of epithelial breakdown was primarily responsible for this patient’s markedly elevated serum CA 19-9 value of greater than 45,000, particularly given the significant decrease in value following surgical resection.

Conclusion
While serum CA 19-9 is a biomarker associated with biliopancreatic malignancy, it is also associated with a number of benign etiologies and cannot reliably be used to differentiate between the two. Our case report further supports the observation that serum CA 19-9 does not have value in predicting malignant versus benign etiology of biliopancreatic masses.

Lessons Learned
Although the case underscores the inaccuracy of serum CA 19-9 as a serological predictor of malignancy, the patient’s symptomatology in the presence of an enlarging hepatic mass was an appropriate indication for resection.

References